MeSH D012852 - sinusitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012852:Â
Sinusitis
D015521:Ethmoid sinusitis
0 Companies
0 Drugs
Success rate
D015522:Frontal sinusitis
0 Companies
0 Drugs
Success rate
D015523:Maxillary sinusitis
D015524:Sphenoid sinusitis
0 Companies
0 Drugs
Success rate
D000092562:Allergic fungal sinusitis
0 Companies
0 Drugs
Success rate
D000096825:Rhinosinusitis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| A.H. Robins Company | Dextromethorphan, Pseudoephedrine, Brompheniramine | Dimetane-dx |  | 1984-08-24 |  |  |
| AbbVie | Cefdinir | Omnicef |  | 1997-12-04 |  |  |
| Acella Pharmaceuticals | Dextromethorphan, Pseudoephedrine, Brompheniramine | Brompheniramine Maleate, Pseudoephedrine Dextromethorphan |  | 2016-09-20 |  |  |
| Alembic Pharmaceuticals | Moxifloxacin | Moxifloxacin |  | 2019-02-13 |  |  |
| ALK-Abelló | Ciprofloxacin | Otiprio | 2029-04-21 | 2015-12-10 |  |  |
| Alkem Laboratories | Dextromethorphan, Pseudoephedrine, Brompheniramine | Brompheniramine Maleate, Pseudoephedrine Dextromethorphan |  | 2020-07-14 |  |  |
| Cefdinir | Cefdinir |  | 2021-02-19 |  |  | |
| Cefpodoxime proxetil | Cefpodoxime Proxetil |  | 2022-05-18 |  |  | |
| Cefuroxime axetil | Cefuroxime Axetil |  | 2010-06-07 |  |  | |
| Allergan | Cefuroxime | Cefuroxime |  | 1993-02-26 |  |  |
| Ciprofloxacin | Ciprofloxacin |  | 2005-01-21 |  |  | |
| Guaifenesin | Guaifenesin |  | 2015-09-03 |  |  | |
| Dextromethorphan, Guaifenesin | Guaifenesin Dextromethorphan |  | 2015-08-31 |  |  | |
| Pseudoephedrine, Guaifenesin | Guaifenesin Pseudoephedrine |  | 2015-05-27 |  |  | |
| Pseudoephedrine, TRIPROLIDINE | Triprolidine Pseudoephedrine |  | 1984-01-13 |  |  | |
| Alpharma | Dextromethorphan, Pseudoephedrine, Brompheniramine | Bromanate |  | 1985-03-07 |  |  |
1
2
3
4
5
6
...
12
>
Clinical Trials
Historical Success Rate
Phase 1
33%1/3
Phase 2
44%12/27
Phase 3
73%30/41
Approved: 19Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
8
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use